{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:43Z","timestamp":1794045703879,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jcrc.2023.154446","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T14:08:27Z","timestamp":1698761307000},"page":"154446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial"],"prefix":"10.1016","volume":"79","author":[{"given":"Pierre-Fran\u00e7ois","family":"Laterre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"S\u00e1nchez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Poll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Wittebole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mart\u00ednez-Sagasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy-Ann","family":"Cadogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"de la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleuterio","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcrc.2023.154446_bb0005","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jcrc.2023.154446_bb0010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7861\/clinmedicine.12-6-538","article-title":"Community-acquired pneumonia","volume":"12","author":"Brown","year":"2012","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jcrc.2023.154446_bb0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0272-5231(05)70237-9","article-title":"Severe community-acquired pneumonia","volume":"20","author":"Ewig","year":"1999","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0020","first-page":"167","article-title":"Severe community-acquired pneumonia","volume":"16","author":"Morgan","year":"2016","journal-title":"s"},{"key":"10.1016\/j.jcrc.2023.154446_bb0025","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0030","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"Torres","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jcrc.2023.154446_bb0035","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/jeccm.2017.12.12","article-title":"Management of severe community acquired pneumonia in the emergency department","volume":"2","author":"Lim","year":"2018","journal-title":"J Emerg Critic Care Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/QCO.0b013e32835ebc6d","article-title":"Long-term prognosis in community-acquired pneumonia","volume":"26","author":"Restrepo","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jcrc.2023.154446_bb0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for Sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jcrc.2023.154446_bb0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fimmu.2017.00339","article-title":"Antimicrobial activity of mesenchymal stem cells: current status and new perspectives of antimicrobial peptide-based therapies","volume":"8","author":"Alcayaga-Miranda","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcrc.2023.154446_bb0055","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","article-title":"Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs","volume":"10","author":"Weiss","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcrc.2023.154446_bb0060","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1164\/rccm.201001-0010OC","article-title":"Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis","volume":"182","author":"Mei","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0065","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Panes","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcrc.2023.154446_bb0070","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/cells8070764","article-title":"Mesenchymal stem cells for perianal Crohn\u2019s disease","volume":"8","author":"Carvello","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jcrc.2023.154446_bb0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","article-title":"Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial","volume":"3","author":"Wilson","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","article-title":"Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial","volume":"7","author":"Matthay","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0085","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.3390\/ijms21228662","article-title":"Mesenchymal stem cells in multiple sclerosis: recent evidence from pre-clinical to clinical studies","volume":"21","author":"Gugliandolo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcrc.2023.154446_bb0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41419-020-2542-9","article-title":"The therapeutic potential of mesenchymal stem cells for cardiovascular diseases","volume":"11","author":"Guo","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jcrc.2023.154446_bb0095","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13287-020-01730-7","article-title":"Efficacy of mesenchymal stem cell therapy for sepsis: a meta-analysis of preclinical studies","volume":"11","author":"Sun","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcrc.2023.154446_bb0100","doi-asserted-by":"crossref","first-page":"s117","DOI":"10.7861\/clinmed.20-2-s117","article-title":"The impact of mesenchymal stem cells on host immunity and disease outcome in bacterial lung infection","volume":"20","author":"Stowell","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jcrc.2023.154446_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-015-0288-1","article-title":"Prospectively defined murine mesenchymal stem cells inhibit Klebsiella pneumoniae-induced acute lung injury and improve pneumonia survival","volume":"16","author":"Hackstein","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.jcrc.2023.154446_bb0110","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1086\/506430","article-title":"Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data","volume":"43","author":"Bauer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2023.154446_bb0115","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1089\/scd.2011.0139","article-title":"Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis","volume":"21","author":"DelaRosa","year":"2012","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.jcrc.2023.154446_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.76.56","article-title":"Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review","volume":"76","author":"Mizuno","year":"2009","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.jcrc.2023.154446_bb0125","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcrc.2023.154446_bb0130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fimmu.2014.00148","article-title":"The life and fate of mesenchymal stem cells","volume":"5","author":"Eggenhofer","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcrc.2023.154446_bb0135","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/sctm.18-0260","article-title":"Human adipose-derived mesenchymal stem cells modify lung immunity and improve antibacterial defense in Pneumosepsis caused by Klebsiella pneumoniae","volume":"8","author":"Perlee","year":"2019","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0140","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"Alvaro-Gracia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jcrc.2023.154446_bb0145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13287-019-1391-x","article-title":"Role of tissue factor in the procoagulant and antibacterial effects of human adipose-derived mesenchymal stem cells during pneumosepsis in mice","volume":"10","author":"Perlee","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jcrc.2023.154446_bb0150","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4252\/wjsc.v7.i2.368","article-title":"Mesenchymal stem cells as a therapeutic tool to treat sepsis","volume":"7","author":"Lombardo","year":"2015","journal-title":"World J Stem Cells"},{"key":"10.1016\/j.jcrc.2023.154446_bb0155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/gut.2008.168534","article-title":"Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis","volume":"58","author":"Gonzalez-Rey","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jcrc.2023.154446_bb0160","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/stem.2891","article-title":"Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single-blind, parallel group, placebo controlled trial","volume":"36","author":"Perlee","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.jcrc.2023.154446_bb0165","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12890-020-01324-2","volume":"20","author":"Laterre","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/arh.2018.06.01","article-title":"Sepsis and community-acquired pneumonia","volume":"2","author":"Ceccato","year":"2018","journal-title":"Annal Res Hospital"},{"key":"10.1016\/j.jcrc.2023.154446_bb0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/17476348.2014.927736","article-title":"Immunomodulatory adjuvant therapy in severe community-acquired pneumonia","volume":"8","author":"Morton","year":"2014","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jcrc.2023.154446_bb0180","first-page":"1:33","article-title":"Current and emerging evidence for immunomodulatory therapy in community-acquired pneumonia","author":"Woods","year":"2017","journal-title":"Annal Res Hospital"},{"key":"10.1016\/j.jcrc.2023.154446_bb0185","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1182\/blood-2016-03-708511","article-title":"Inducible epithelial resistance protects mice against leukemia-associated pneumonia","volume":"128","author":"Leiva-Juarez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcrc.2023.154446_bb0190","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.4049\/jimmunol.1500124","article-title":"Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection","volume":"194","author":"Jose","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jcrc.2023.154446_bb0195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.chest.2017.03.056","article-title":"The role of neutrophil elastase inhibitors in lung diseases","volume":"152","author":"Polverino","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jcrc.2023.154446_bb0200","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1473-3099(18)30805-3","article-title":"CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial","volume":"19","author":"Laterre","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcrc.2023.154446_bb0205","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jcrc.2023.154446_bb0210","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3389\/fimmu.2019.01244","article-title":"Dissecting allo-sensitization after local administration of human allogeneic adipose mesenchymal stem cells in perianal fistulas of Crohn\u2019s disease patients","volume":"10","author":"Avivar-Valderas","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcrc.2023.154446_bb0215","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/icb.2012.67","article-title":"Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?","volume":"91","author":"Griffin","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jcrc.2023.154446_bb0220","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/cells8101160","article-title":"Thrombogenic risk induced by intravascular mesenchymal stem cell therapy: current status and future perspectives","volume":"8","author":"Coppin","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jcrc.2023.154446_bb0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41100-018-0182-7","article-title":"Using Sepsis-3 criteria to predict prognosis of patients receiving continuous renal replacement therapy for community-acquired sepsis: a retrospective observational study","volume":"4","author":"Akiu","year":"2018","journal-title":"Renal Replacem Therapy"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944123001958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944123001958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:52:46Z","timestamp":1760125966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944123001958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":45,"alternative-id":["S0883944123001958"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2023.154446","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2023.154446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"154446"}}